Parallax Health Sciences, Inc. Announces Corporate Update Conference Call
SANTA MONICA, CA / ACCESSWIRE / Parallax Health Sciences, Inc. (“Parallax” or the “Company”) (PRLX) has scheduled a public conference call on Thursday, October 30, 2014, at 2:30pm PDT (5:30pm EDT). During the call, Edward W. Withrow III, the Company’s Chairman, and Mr. J. Michael Redmond, the Company’s President and CEO, will provide a corporate update.
------------------------------------------------------------------ |Call Length: |1 Hour | ------------------------------------------------------------------ |Conference Date: |Thursday, 10/30/2014 | ------------------------------------------------------------------ |Conference Start Time: |2:30pm PDT (5:30pm EDT) | ------------------------------------------------------------------ |Participant Dial-In Number: |1-857-232-0158 | Access Code 964308| ------------------------------------------------------------------
About Parallax Health Sciences, Inc.:
Parallax Health Sciences, Inc. is a fully reporting Nevada corporation traded on the OTCQB under the symbol "PRLX". The Company is headquartered in Cambridge, MA. The Company’s wholly owned subsidiary, Endeavor Sciences, Inc. (“Endeavor”) is a bio-medical company focused on infectious diseases, which owns a line of FDA approved Point of Care diagnostic tests on a single proprietary platform. Endeavor is developing a novel, handheld diagnostic testing system that is simple, rapid and elegant, offering the potential to transform the diagnostic landscape by transitioning critical tests from the centralized lab directly to the hands of the physician or clinicians. The Company’s focus is on tests that detect and/or monitor infectious diseases and combine innovative technologies that provide accessible, practical and rapid point of care in vitro diagnostics. The tests are based on the Company’s Target System, its FDA Approved Platform that is centered on the Target System VT1000, an FDA Approved bench top fluorescence immunoassay spectrum analyzer and its innovative flow through Target System test cartridges. For more information: http://www.parallaxhealthsciences.com/
Forward-Looking Statements:
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond the Company’s control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in the Company’s reports filed with the SEC. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Calli Bucci,
Corporate Secretary
Parallax Health Sciences, Inc.
callib@parallaxhealthsciences.com
310.899.4442
Investor Contact:
Mark Bernhard
Capital Group Communications
mark@capitalgc.com
415.332.7200
SOURCE: Parallax Health Sciences, Inc.
